CIRM Funded Clinical Trials
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers
Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$7,141,843
Trial Sponsor:
Tachyon Therapeutics, Inc
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
